BioStock Studio: Elicera’s immuno-oncology platform iTANK reaches high-impact journal
Gothenburg-based gene therapy company Elicera Therapeutics recently announced the publication of a scientific article describing the mechanism-of-action of its universal CAR T-cell enhancement technology platform iTANK. The publication came in Nature Biomedical Engineering, one of the highest ranked scientific journals in the world. CSO and co-founder Professor Magnus Essand joined BioStock Studio via link from Uppsala to tell us more about iTANK and the importance of this publication.
Watch the full interview with Elicera's CSO and Co-founder Magnus Essand at biostock.se:
This is a press release from BioStock - Connecting Innovation & Captial. https://www.biostock.se/